Peptides for inhibiting chemokine binding to chemokine...

Details Peptides for inhibiting chemokine binding to chemokine... Peptides for inhibiting chemokine binding to chemokine...

2009-01-22

2011-10-18

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S327000, C424S184100

Reexamination Certificate

active

08039440

ABSTRACT:
Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.

REFERENCES:
patent: 5840693 (1998-11-01), Eriksson et al.
patent: 2003/0027751 (2003-02-01), Kovesdi et al.
patent: 2003/0166004 (2003-09-01), Gyuris et al.
patent: 2004/0171552 (2004-09-01), Peled et al.
patent: WO 02/061087 (2002-08-01), None
patent: WO 03/072599 (2003-09-01), None
Official Action Dated Aug. 6, 2007 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/649,873.
Official Action Dated Jun. 6, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/649,873.
Misumi et al. “A Cyclic Dodecapeptide-Multiple-Antigen Peptide Conjugate From the Undecapeptidyl Arch (From Arg168 to Cys178) of Extracellular Loop 2 in CCR5 as a Novel Human Immunodeficiency Virus Type 1 Vaccine”, Journal of Virology, 75(23): 11614-11620, 2001.
Invitation to Remedy Deficiencies Pursuant to Rule 30(3) EPC / Rule 163(3) EPC Dated May 3, 2010 From the European Patent Office Re.: Application No. 10153629.0.
Notice of Allowance Dated Oct. 7, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/649,873.
Official Action Dated Nov. 1, 2006 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/649,873.
Response Dated Jun. 29, 2010 to Invitation to Remedy Deficiencies Pursuant to Rule 30(3) EPC / Rule 163(3) EPC of May 3, 2010 From the European Patent Office Re.: Application No. 10153629.0.
Communication Pursuant to Article 96(2) EPC Dated Sep. 5, 2005 from the European Patent Office Re.: Application No. 03743008.9.
International Search Report Dated Sep. 24, 2003 From the International Searching Authority Re.: Application No. PCT/IL03/00155.
Official Action Dated Apr. 30, 2008 From the US Patent and Trademark Office Re.: U.S. Appl. No. 10/649,873.
Baggiolini et al. “CC Chemokines in Allergic Inflammation”, Immunology Today, 15(3): 127-133, 1994.
Burmer et al. “G Protein-Coupled Receptor (GPCR) Antigenic Peptide SEQ ID No. 944”, Retrieved From EBI Database Accession No. ABP82271, 2003. Abstract.
Cocchi et al. “Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factor Produced by CD8+ T Cells”, Science, 270: 1811-1815, 1995.
Hay et al. “Interleukin-8 Receptor Antagonists in Pulmonary Diseases”, Current Opinion in Pharmacology, 1: 242-247, 2001.
Hayashi et al. “Synthetic IIexa- and Heptapeptides That Inhibit IL-8 From Binding to and Activating Human Blood Neutrophils 1”, The Journal of Immunology, 154: 814-824, 1995.
Ma et al. “Impaired B-Lymphopoiesis, Myelopoiesis, and Derailed Cerebellar Neuron Migration in CXCR4- and SDF-1-Deficient Mice”, Proc. Natl. Acad. Sci. USA, 95: 9448-9453, 1998.
Misumi et al. “A Novel Cyclic Peptide Immunization Strategy for Preventing HIV-1/AIDS Infection and Progression”, The American Society for Biochemistry and Molecular Biology, P.1-38, 2003.
Mukaida et al. “Interleukin-8 and Other CXC Chemokines”, The Cytokine Handbook, 4th Ed., 2: 1065-1081, 2003.
Müller et al. “Involvement of Chemokine Receptors in Breast Cancer Metastasis”, Nature, 410: 50-56, 2001.
Proudfoot et al. “The Strategy of Blocking the Chemokine System to Combat Disease”, Immunological Reviews, 177: 247-256, 2000. p.253-255.
Stricter et al. “The Functional Role of the ELR Motif in CXC Chemokine-Mediated Angiogenesis”, The Journal of Biological Chemistry, 270(45): 27348-27357, 1995.
Vaddi et al. “Regulation of Monocyte integrin Expression by β-Family Chemokines”, The Journal of Immunology, 153: 4721-4732, 1994.

Affiliated with

Also associated with

Rating

Peptides for inhibiting chemokine binding to chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptides for inhibiting chemokine binding to chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for inhibiting chemokine binding to chemokine... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4278792